"Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes Correspondence

  

Authors:	Pietzak, E. J.; Al-Ahmadie, H.; Walasek, A.; Bajorin, D. F.; Rosenberg, J. E.; Bochner, B. H.; Solit, D. B.; Iyer, G.
Title:	"Primary" and "secondary" muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes
Keywords:	cancer chemotherapy; treatment response; primary tumor; gene mutation; overall survival; missense mutation; cisplatin; adjuvant therapy; cancer patient; letter; biological marker; dna damage; dna repair; metastasis; cohort analysis; practice guideline; cancer specific survival; cystectomy; outcomes research; neoadjuvant chemotherapy; personalized medicine; recurrence free survival; clinical trial (topic); muscle invasive bladder cancer; high throughput sequencing; xeroderma pigmentosum group d protein; non muscle invasive bladder cancer; intention to treat analysis
Journal Title:	Translational Cancer Research
Volume:	8
Issue:	Suppl. 6
ISSN:	2218-676X
Publisher:	Pioneer Bioscience Publishing Company
Date Published:	2019-12-01
Start Page:	S642
End Page:	S644
Language:	English
DOI:	10.21037/tcr.2019.12.21
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078930885&doi=10.21037%2ftcr.2019.12.21&partnerID=40&md5=b5bfdbd1a7ef8c01da293ee9efa3dbb9
Notes:	Letter -- Export Date: 2 March 2020 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/161973